Dupilumab is in development for the treatment of children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) uncontrolled with currently available therapies. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.
Dupilumab acts by blocking certain proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13) and mediating the pathways involved in the inflammatory process in AD. Dupilumab is taken subcutaneously (SC) and is currently licensed for the treatment of moderate to severe AD in adults who are candidates for systemic therapy. If licensed, dupilumab will offer an additional treatment option for children aged ≥ 6 to < 12 years with severe AD.
Bimekizumab is in clinical development for moderate to severe chronic plaque psoriasis. Plaque psoriasis is a persistent, long lasting chronic inflammatory disease causing red, flaky and itchy patches of skin commonly appearing on the elbows, knees, scalp and lower back. Plaque psoriasis is an autoimmune disease, meaning that the immune cells which usually fight infection attack the body’s own tissues instead, in this case, the skin. Treatment is determined by the type and severity of psoriasis, and the area of skin affected, and may include a combination of topical, phototherapy and systemic (oral or injected) therapies.